Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

elephone replay will be available through November 6, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non- nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598 and ANA773, including the trial design, occurrence, timing, and pace of future clinical trials, the timing for obtaining viral load data and expectations regarding such data, as well as the anticipated future clinical benefits of ANA598 and ANA773. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements. For example, the results of preclinical studies and early clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... The empty capsules market is experiencing ... and technological innovations in the empty capsules market. ... the growth of the empty capsules market. , ... Scope of Report , The report will enrich ... firms to gauge the pulse of the market ...
(Date:12/19/2014)... -- Egenix, Inc. is pleased to announce that Lionel ... to succeed Donald Fresne ; Mr. Fresne has also ... member of the Board.  In recognition of the many contributions ... almost twenty years, the Board designated Mr. Fresne as Chairman ... a Search Committee to find a suitable replacement with Biotech ...
(Date:12/17/2014)... The Activated Carbon Manufacturing ... why IBISWorld updated its original industry research report. ... an intensified focus on environmental policy. Over the five ... for power plants and a range of other industrial ... Analyst Sarah Kahn, “a range of downstream industrial sectors ...
(Date:12/17/2014)... Achim Noack has been named global vice ... this position, Noack will assist Jerry Stoller, CEO and ... strategy and supervise global marketing management and implementation of ... knowledge and experience in the crop protection industry,” says ... innovative thinking will be a great asset for Stoller ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... June 5, 2011 Northwest Biotherapeutics (OTC.BB: NWBO) today ... of financing arrangements, including a $3 million investment already ... further funding on fixed, specified and favorable terms, at ... chooses.  This series of financing arrangements will provide a ...
... Recent biopharmaceutical product launches have produced both noteworthy failures ... with a continually evolving launch landscape, organizations are rethinking ... current launch environment. In a new ... and failure points facing new product launches, Best Practices, ...
... 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: ... financial results for the fourth quarter and full year of ... close in the US.   The Company will ... June 13, 2011 to discuss its financial performance and give ...
Cached Biology Technology:Northwest Biotherapeutics Announces Series of Financing Arrangements 2Northwest Biotherapeutics Announces Series of Financing Arrangements 3Northwest Biotherapeutics Announces Series of Financing Arrangements 4Creating a Road Map for Successful Cardiovascular New Product Launch 2China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results 2
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/10/2014)... CIE San Diego has launched an innovative ... tissue that enhances care coordination among social service and ... information; earned a second $1 million grant from the ... aging in community and; will be recognized as a ... 4-6p. CIE San Diego today announced ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... Austin researchers have discovered how to extract and use information ... from the focus distance, a feat only accomplished by human ... camera, the human eye has an auto-focusing system, but human ... not require trial and error to focus an object. ...
... Texas Advanced Computing Center (TACC) at the University of ... and support a world-class supercomputer with comprehensive computing and ... Made possible by a $27.5 million grant from the ... of the NSF "eXtreme Digital" (XD) program, an integrating ...
... some people with asthma do not respond well to inhaled ... Researchers found that asthma patients who have two copies of ... steroid inhalers as those with two copies of the regular ... National Heart, Lung, and Blood Institute (NHLBI), part of the ...
Cached Biology News:Researchers develop optimal algorithm for determining focus error in eyes and cameras 2Stampede charges computational science forward in tackling complex societal challenges 2Stampede charges computational science forward in tackling complex societal challenges 3Stampede charges computational science forward in tackling complex societal challenges 4NIH-funded study connects gene variant to response to asthma drugs 2
Anti Human S14G-Humanin Polyclonal Antibody...
... a positive control for ChIP assays. Efficient ... vivo is a crucial step for the ... is probably the most important parameter. Two ... should be taken into account: first, an ...
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
Biology Products: